查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1856292

抗體契約製造市場：下游－2025-2032年全球預測

Antibodies Contract Manufacturing Market by Downstream - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，抗體契約製造市場規模將達到 421.7 億美元，複合年成長率為 11.19%。

主要市場統計數據
基準年 2024 180.4億美元
預計年份：2025年 200.5億美元
預測年份：2032年 421.7億美元
複合年成長率 (%) 11.19%

全面介紹抗體契約製造領域，重點在於供應鏈的複雜性、營運韌性、技術推動因素和相關人員的需求。

抗體契約製造領域正經歷著營運高度複雜化的時期，這主要得益於技術進步、監管要求和不斷變化的商業性需求。本書將讀者帶入一個快速專業化的行業，在這個行業中，製造商和客戶都將品質的穩定性、可擴展的工作流程和可重複的供應鏈放在首位。隨著治療方式的多樣化和研發週期的縮短，受託製造製造商的價值日益凸顯，不僅體現在其營運方面的專業知識，也體現在其整合上下游流程、打造穩健的端到端解決方案以降低轉換風險的能力上。

分析抗體醫藥品受託製造模式下正在發生的變革性運作、技術和監管變化，這些變化正在重新定義品質預期和夥伴關係動態。

過去幾年，抗體契約製造營運的預期發生了顯著變化。自動化數位化已從先導計畫擴展到核心流程控制，從而能夠對關鍵品質屬性進行嚴格監控，並確保研發和商業化階段的資料連續性。同時，一次性技術和模組化設備縮短了部署時間，提高了靈活性，使服務供應商無需進行大規模設備維修即可服務多元化的客戶群。

分析2025年美國新的關稅措施將如何影響抗體生產相關人員的採購決策、供應鏈韌性和籌資策略。

美國將於2025年實施新的關稅，無疑增加了抗體契約製造生態系統中採購和成本管理的複雜性。雖然這些關稅不會改變科學研究工作流程，但會影響關鍵試劑、一次性組件和專用設備的採購成本，迫使生產商和贊助商重新評估其供應商選擇標準和庫存策略。為此，許多公司正在重新評估其近期籌資策略，優先考慮擁有多元化製造地和成熟跨境物流能力的供應商。

透過細分主導洞察，將下游層析法與上游生物製程要素連結起來，從而指導產能設計和製程整合選擇的營運重點。

細緻的細分分析揭示了不同製程領域及其子組件如何驅動抗體生產價值鏈中的產能需求和投資重點。從下游角度來看，關鍵操作領域包括層析法純化、過濾和離心、超過濾和滲濾，每個領域都有其特定的技術規格和設備需求。層析法純化本身可細分為疏水交互作用層析法、離子交換層析法和蛋白A層析法，每種方法都會影響樹脂處理、緩衝液消費量和一次性使用適用性，進而影響下游製程佈局和運作成本。

區域分析重點闡述了在美洲、歐洲、中東和非洲以及亞太地區的策略佈局如何影響監管合規能力規劃和供應鏈彈性。

區域動態對合約研究公司和申辦方的策略重點有顯著影響。了解美洲、歐洲、中東和北非以及亞太地區之間的細微差別，對於有效的產能規劃和監管應對至關重要。在美洲，商業規模的生產能力以及與主要生物製藥中心的接近性通常有利於專案從研發階段快速過渡到臨床試驗階段，而監管機構則強調完善的文件記錄和核准後監管，這可能會影響生產連續性計劃。相反，在中東和北非地區，監管系統更為細分，需要靈活的品質系統和本地市場專業知識來管理跨司法管轄區的放行和檢測。

對競爭格局進行全面分析，探討卓越營運和策略夥伴關係如何決定差異化和服務可靠性。

主要企業的抗體醫藥品契約製造公司之間的競爭格局體現了技術深度、綜合服務以及策略夥伴關係關係的融合。市場領導者透過提供從細胞系開發和製程最佳化到規模化生產和商業化支援的全面解決方案來脫穎而出，從而降低交接風險並加快客戶的研發進程。其他公司則透過專注於特定領域來獲得競爭優勢，例如專注於高效的下游平台或先進的層析法技術以應對複雜的雜質譜。與設備和一次性用品供應商的技術合作也能透過實現快速製程轉移和高效的供應管道來創造競爭優勢。

為領導者提供以優先事項為導向、切實可行的建議，以增強流程整合、規模敏捷性、供應鏈韌性和數位化，從而獲得永續的競爭優勢。

產業領導者應優先考慮一系列切實可行的舉措，使能力投資與新興技術和監管要求保持一致。首先，推動上游和下游團隊之間的跨環節流程整合，以減少交接環節的差異並縮短轉移週期。將製程開發科學家、品質專家和放大工程師納入協作專案團隊，可以改善決策，並在下游瓶頸出現之前加以預防。

透明的混合調查方法結合了專家訪談、二手技術資訊和基於場景的檢驗，確保了可靠的可重複性和實際有效性。

本分析的調查方法結合了定性和定量方法，以確保研究結果的穩健性、可重複性和實用性。主要研究包括對技術領導者、製造企業高管和採購專家進行結構化訪談，以收集他們對營運限制、產能投資和供應商選擇標準的第一手觀點。這些定性資訊與來自監管指導文件、行業標準和同行評審文獻的二級資訊來源進行三角驗證，以檢驗技術論點並整合觀察到的趨勢。

指導相關人員順利完成抗體生產轉型的策略要務：風險緩解策略和機會管道的簡要概述

總而言之，抗體契約製造正經歷著由技術創新、監管完善和不斷變化的商業性預期所驅動的結構性變革。上游生產效率的提升與下游純化策略的結合是提高產量和降低轉換風險的關鍵，而關稅和貿易因素也日益影響採購和供應鏈的設計。區域動態的增加更增添了複雜性，需要靈活的佈局和統一的品質系統來支援跨區域專案。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將人工智慧和機器學習整合到抗體生產流程分析中，以提高生產效率
  • 採用靈活且可擴展的一次性反應器系統進行單株抗體生產
  • 實施連續生物製造平台可降低抗體合約生產商的成本並縮短生產週期。
  • 先進的宿主細胞株工程技術可提高單株抗體的高效價和製程一致性。
  • 監管協調計劃旨在促進全球抗體契約製造的核准管道。
  • 生物相似抗體CMC服務的出現滿足了市場對具成本效益生技藥品日益成長的需求。
  • 透過整合數位雙胞胎建模和即時監測來最佳化抗體生產流程
  • 擴大個人化免疫療法抗體生產規模，以支持特定癌症和自體免疫疾病的治療
  • 在抗體合約生產商處實施永續綠色生產實踐，以減少對環境的影響
  • 利用高性能篩檢平台篩選抗體候選藥物，加速開發平臺。

第6章美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

第8章：下游抗體契約製造市場

  • 層析法純化
    • 疏水交互作用層析法
    • 離子交換層析法
    • 蛋白質A層析法
  • 過濾和離心
  • 超過濾和滲濾
  • 上游
    • 反應器運行
    • 細胞株構建
    • 培養基和飼料的製備

第9章 抗體契約製造市場：依地區分類

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第10章：按組別分類的抗體契約製造市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第11章 各國抗體契約製造市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第12章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Lonza Group Ltd
    • Samsung Biologics Co., Ltd
    • 藥明生物（香港）有限公司
    • Catalent, Inc.
    • Boehringer Ingelheim International GmbH
    • Fujifilm Diosynth BIoTechnologies US, LLC
    • Merck KGaA
    • AGC Biologics Inc
    • Thermo Fisher Scientific Inc.
    • Rentschler Biopharma SE
Product Code: MRR-742BD517AE6B

The Antibodies Contract Manufacturing Market is projected to grow by USD 42.17 billion at a CAGR of 11.19% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 18.04 billion
Estimated Year [2025] USD 20.05 billion
Forecast Year [2032] USD 42.17 billion
CAGR (%) 11.19%

Comprehensive introduction to antibody contract manufacturing landscape emphasizing supply chain complexities operational resilience technological enablers and stakeholder imperatives

The antibody contract manufacturing landscape is experiencing a period of intense operational refinement driven by technological advances, regulatory expectations, and shifting commercial imperatives. This introduction situates the reader in a rapidly professionalizing sector where manufacturers and clients alike prioritize consistent quality, scalable workflows, and reproducible supply chains. As therapeutic modalities diversify and development timelines compress, contract manufacturers are being evaluated not only for unit operations expertise but for their ability to integrate upstream and downstream processes into robust end-to-end solutions that reduce translational risk.

In practice, this means that strategic decisions now extend beyond single process improvements to include platform selection, vendor interoperability, and lifecycle management of biologics. Consequently, stakeholders are placing greater emphasis on cross-functional collaboration, aligning process development teams with quality and regulatory groups early in the program lifecycle to preempt downstream bottlenecks. Furthermore, investment in flexible manufacturing architectures and advanced analytics has become a differentiator that supports faster scale-up, improved yield consistency, and tighter process control.

Looking ahead, the interplay between scientific innovation and operational excellence will determine competitive advantage. Companies that adopt modular production capabilities, embrace quality-by-design principles, and cultivate resilient supply ecosystems will be positioned to meet the accelerating demand for specialized antibody formats. This introduction lays the groundwork for a deeper analysis of systemic shifts, tariff implications, segmentation dynamics, regional nuances, competitive behavior, and actionable guidance for leaders intent on navigating this evolving market environment.

Analysis of transformative operational technological and regulatory shifts that are redefining antibody contract manufacturing models quality expectations and partnership dynamics

The past several years have seen transformative shifts that are recalibrating expectations across antibody contract manufacturing operations. Automation and digitization have migrated from pilot projects to core process control, enabling tighter monitoring of critical quality attributes and delivering data continuity across development and commercial stages. In parallel, single-use technologies and modular facilities have reduced time-to-deploy and increased flexibility, allowing service providers to accommodate diverse client portfolios without extensive retrofitting.

Cell-line engineering and process intensification are raising the bar for upstream productivity, while innovations in chromatography and impurity clearance are reshaping downstream strategies. As a result, the traditional delineation between development and manufacturing partners is blurring; integrated service models that span cell-line development, process transfer, and clinical supply are gaining traction because they reduce handoff risk and accelerate timelines. Moreover, a growing emphasis on digital twins and model-based control is permitting predictive maintenance and process optimization that materially improve batch consistency.

Regulatory authorities have also adapted, placing new emphasis on data integrity, lifecycle management, and comparability for novel modalities. Consequently, contract manufacturers are investing in expandable quality management systems and harmonized documentation to ensure readiness for stricter inspections and cross-border transfers. Meanwhile, strategic sourcing is evolving: supply chain resilience is now as important as unit cost, and companies are diversifying reagent and consumable suppliers to mitigate single-source vulnerabilities. Taken together, these transformative shifts are not incremental; they represent a step change in how manufacturing capacity is organized, governed, and commercialized, and they compel stakeholders to rethink partnerships, capability roadmaps, and long-term investment strategies.

Examination of how new United States tariff policies in 2025 are influencing sourcing decisions supply chain resilience and procurement strategies for antibody manufacturing stakeholders

The introduction of new United States tariff measures in 2025 has introduced an added layer of complexity to procurement and cost management in the antibody contract manufacturing ecosystem. While tariffs do not alter scientific workflows, they influence the economics of sourcing critical reagents, single-use components, and specialized equipment, prompting manufacturers and sponsors to reassess supplier selection criteria and inventory policies. In response, many organizations have revisited their near-term sourcing strategies to prioritize suppliers with diversified manufacturing footprints and established cross-border logistics capabilities.

Consequently, firms are accelerating localization of key supply lines where feasible and negotiating longer-term procurement agreements to stabilize input availability. These changes have also elevated the importance of total landed cost assessments in supplier evaluation frameworks, with procurement teams integrating tariff exposure, customs lead times, and compliance risks into their decision matrices. As a transitional measure, some manufacturers have increased strategic stock levels for critical low-turnover components to buffer against disruption, while others have reconfigured production schedules to align with expected customs clearances and seasonal shipping constraints.

In addition, the tariff environment has intensified due diligence on supply chain transparency, particularly for items sourced through multi-tiered vendors. Contract manufacturers and sponsors are increasingly demanding greater traceability, origin documentation, and contingency planning as part of contractual terms. Collectively, these adjustments reflect a broader shift: geopolitical and trade policy variables now sit alongside quality and regulatory considerations when designing resilient manufacturing strategies, and organizations that proactively incorporate these factors into their planning will be better positioned to maintain continuity and service levels under evolving trade regimes.

Segment-driven insights connecting downstream chromatography modalities and upstream bioprocess elements to capability design operational priorities and process integration choices

A nuanced segmentation analysis reveals how distinct process domains and their subcomponents drive capability requirements and investment priorities across the antibody manufacturing value chain. When viewed through a downstream lens, key operational areas encompass chromatography purification, filtration and centrifugation, and ultrafiltration and diafiltration, each of which imposes specific technical specifications and facility needs. Chromatography purification itself fragments into hydrophobic interaction chromatography, ion exchange chromatography, and Protein A chromatography, and each of these modalities influences resin handling practices, buffer consumption, and single-use compatibility, thereby shaping downstream footprint and operating expenditure profiles.

Upstream activities interconnect tightly with downstream choices and are composed of bioreactor operation, cell line development, and media and feed preparation. Decisions made during cell line development, including clone selection and expression systems, have outsized implications for downstream burden and purification strategy; similarly, bioreactor operation parameters determine impurity profiles and process robustness, which cascade into chromatography load and filtration sequencing. Media and feed preparation further affect process control and consistency, and the selection of feeds compatible with intensified or perfusion-based bioreactors can shift capital and consumables allocation between upstream and downstream units.

Given this segmentation, companies must prioritize interoperability across unit operations and invest in platform technologies that reduce variability at handoffs. In practice, integrated process development that aligns chromatography modalities with expected impurity spectra and upstream productivity yields smoother transfers and accelerates clinical supply readiness. Therefore, segment-level optimization, rather than isolated improvements, delivers disproportionate gains in throughput, quality, and time-to-clinic, and it should guide capability roadmaps and partner selection criteria.

Regional analysis highlighting how strategic footprints across the Americas Europe Middle East & Africa and Asia-Pacific shape regulatory compliance capacity planning and supply resilience

Regional dynamics materially influence strategic priorities for contract manufacturers and sponsors, and recognizing the nuanced differences among the Americas, Europe Middle East & Africa, and Asia-Pacific regions is essential for effective capacity planning and regulatory navigation. In the Americas, commercial-scale capacity and proximity to major biopharma hubs often favor rapid program transition from development to clinic, while regulatory authorities emphasize robust documentation and post-approval surveillance that can influence manufacturing continuity planning. Conversely, Europe Middle East & Africa exhibits a more fragmented regulatory mosaic, which necessitates flexible quality systems and localized market expertise to manage multi-jurisdictional releases and inspections.

Asia-Pacific presents a different set of considerations, including rapidly expanding local manufacturing capabilities, varying regulatory maturity across markets, and cost-competitive supply chains for consumables and support services. In response, many global and regional contract manufacturers are establishing hybrid footprints that combine strategic sites in each of these regions to balance speed-to-market, cost-efficiency, and risk mitigation. Moreover, cross-regional partnerships and tolling arrangements have emerged as pragmatic solutions to address capacity fluctuations and national regulatory preferences. As cross-border supply chains become increasingly sophisticated, stakeholders are investing in regional supply chain orchestration capabilities and harmonized quality management to reduce friction in product transfers across these diverse geographies.

Ultimately, regional strategy is no longer solely about cost, but about positioning firms to respond to regulatory expectations, secure talent pools, and localize critical inputs. By aligning facility capabilities and service offerings with the specific operational and regulatory realities of the Americas, Europe Middle East & Africa, and Asia-Pacific, manufacturers and sponsors can optimize program execution and shorten timelines for global development and commercialization.

Competitive landscape synthesis describing how capability integration operational excellence and strategic partnerships determine differentiation and service reliability

Competitive positioning among key companies in the antibody contract manufacturing space reflects a blend of technical depth, integrated service offerings, and strategic partnerships. Market leaders differentiate by offering holistic solutions spanning cell-line development, process optimization, scale-up, and commercialization support, thereby reducing handoff risk and accelerating client timelines. Others achieve differentiation through niche specialization, for example by focusing on high-efficiency downstream platforms or advanced chromatography capabilities that address challenging impurity profiles. Technology partnerships with instrument and single-use suppliers also create competitive advantages by enabling faster process transfers and validated supply channels.

In addition to technical capabilities, operational excellence is a significant discriminator. Firms that invest in robust quality management systems, harmonized documentation practices, and transparent regulatory interactions gain trust among sophisticated sponsors whose programs demand predictable outcomes. Strategic alliances and networked manufacturing models further expand service reach and mitigate capacity shortfalls, while mergers and capacity-sharing agreements have become common methods to rapidly increase geographic coverage and expand modality expertise. Importantly, client selection criteria increasingly factor in a provider's ability to deliver end-to-end traceability, data continuity, and a documented track record of successful tech transfers.

Consequently, companies that combine process innovation, operational rigor, and flexible commercial models are best positioned to capture demanding partnerships. For procurement teams and investors, assessing the strength of a provider's integration across development and manufacturing, rather than isolated capabilities, yields a clearer view of long-term service reliability and strategic fit.

Priority oriented and actionable recommendations for leaders to enhance process integration scale agility supply resilience and digitalization for sustainable competitive advantage

Industry leaders should prioritize a set of actionable initiatives that align capacity investments with emerging technological and regulatory imperatives. First, elevate cross-disciplinary process integration between upstream and downstream teams to reduce handoff variability and shorten transfer cycles. Embedding process development scientists, quality experts, and scale-up engineers in joint program teams improves decision-making and preempts downstream bottlenecks, which accelerates development velocity while preserving product quality.

Second, adopt flexible manufacturing designs and modular facility approaches that support rapid repurposing and scale adjustments. By combining single-use technologies with modular cleanroom architectures, organizations can increase responsiveness to varied client demands without incurring the long lead times associated with traditional capital projects. Third, strengthen supply chain resilience by diversifying sourcing across geographies and qualifying multiple suppliers for critical reagents and components; this reduces exposure to tariff shifts and logistics disruptions. Fourth, invest in digital infrastructure that supports real-time analytics, process modeling, and electronic batch records to improve traceability and facilitate regulatory submissions.

Finally, pursue strategic partnerships that extend capabilities rather than replicate them. Alliances that fill gaps in chromatography expertise, cell-line engineering, or regional regulatory know-how can provide near-term capacity and skill enhancements while preserving capital flexibility. Implementing these recommendations will allow organizations to improve operational agility, reduce program risk, and maintain competitive service offerings in a landscape defined by rapid scientific and commercial evolution.

Transparent mixed methodologies combining primary expert interviews secondary technical sources and scenario based validation to ensure robust reproducibility and practical relevance

The research methodology underpinning this analysis combines qualitative and quantitative approaches designed to ensure robustness, reproducibility, and practical relevance. Primary research included structured interviews with technical leaders, manufacturing executives, and procurement specialists to capture first-hand perspectives on operational constraints, capability investments, and supplier selection criteria. These qualitative inputs were triangulated with secondary source material drawn from regulatory guidance documents, industry standards, and peer-reviewed literature to validate technical assertions and to contextualize observed trends.

Analytical workflows employed process mapping to identify critical handoff points between upstream and downstream activities, and scenario analysis to evaluate responses to supply chain shocks and tariff changes. Validation rounds with subject matter experts refined interpretations and ensured that recommended actions reflect operational realities. Where appropriate, cross-case comparisons were used to surface best practices and to highlight variations in regional regulatory approaches and facility architectures. Throughout, emphasis was placed on transparent documentation of assumptions and data provenance so that readers can adapt the methodology to their internal audit or compliance frameworks.

This mixed-methods approach ensures that conclusions are grounded in practitioner experience and supported by technical literature, while remaining adaptable to specific program-level questions and operational constraints.

Concise synthesis of strategic imperatives risk mitigation tactics and opportunity pathways to guide stakeholders through antibody manufacturing transitions

In sum, antibody contract manufacturing is undergoing a period of structural evolution driven by technological innovation, regulatory refinement, and shifting commercial expectations. The interplay between upstream productivity enhancements and downstream purification strategies is central to improving throughput and reducing translational risk, while tariff and trade considerations increasingly influence procurement and supply chain design. Regional dynamics add another layer of complexity that requires adaptable footprints and harmonized quality systems to support multi-jurisdictional programs.

Organizations that integrate process development with manufacturing, invest in flexible and digital-enabled facilities, and pursue targeted partnerships will secure operational advantages and mitigate exposure to external shocks. By focusing on interoperability across unit operations, strengthening supply chain transparency, and aligning regional strategies with regulatory realities, stakeholders can better navigate the evolving environment and deliver reliable outcomes for complex antibody modalities. The concluding synthesis underscores the need for a proactive, integrated approach to capability development and commercial strategy.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of artificial intelligence and machine learning in antibody process analytics to enhance manufacturing efficiency
  • 5.2. Adoption of single use bioreactor systems for flexible and scalable monoclonal antibody production
  • 5.3. Implementation of continuous biomanufacturing platforms to reduce costs and accelerate antibody CMO timelines
  • 5.4. Advanced host cell line engineering drives higher monoclonal antibody titers and process consistency
  • 5.5. Regulatory harmonization initiatives facilitating global antibody contract manufacturing approval pathways
  • 5.6. Emergence of biosimilar antibody CMC service offerings to meet rising demand for cost effective biologics
  • 5.7. Integration of digital twin modeling and real time monitoring to optimize antibody manufacturing processes
  • 5.8. Expansion of personalized immunotherapy antibody manufacturing to support niche oncology and autoimmune treatments
  • 5.9. Implementation of sustainable green manufacturing practices to reduce environmental impact in antibody CMOs
  • 5.10. Adoption of high throughput screening platforms to accelerate antibody candidate selection and development pipelines

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antibodies Contract Manufacturing Market, by Downstream

  • 8.1. Chromatography Purification
    • 8.1.1. Hydrophobic Interaction Chromatography
    • 8.1.2. Ion Exchange Chromatography
    • 8.1.3. Protein A Chromatography
  • 8.2. Filtration And Centrifugation
  • 8.3. Ultrafiltration And Diafiltration
  • 8.4. Upstream
    • 8.4.1. Bioreactor Operation
    • 8.4.2. Cell Line Development
    • 8.4.3. Media And Feed Preparation

9. Antibodies Contract Manufacturing Market, by Region

  • 9.1. Americas
    • 9.1.1. North America
    • 9.1.2. Latin America
  • 9.2. Europe, Middle East & Africa
    • 9.2.1. Europe
    • 9.2.2. Middle East
    • 9.2.3. Africa
  • 9.3. Asia-Pacific

10. Antibodies Contract Manufacturing Market, by Group

  • 10.1. ASEAN
  • 10.2. GCC
  • 10.3. European Union
  • 10.4. BRICS
  • 10.5. G7
  • 10.6. NATO

11. Antibodies Contract Manufacturing Market, by Country

  • 11.1. United States
  • 11.2. Canada
  • 11.3. Mexico
  • 11.4. Brazil
  • 11.5. United Kingdom
  • 11.6. Germany
  • 11.7. France
  • 11.8. Russia
  • 11.9. Italy
  • 11.10. Spain
  • 11.11. China
  • 11.12. India
  • 11.13. Japan
  • 11.14. Australia
  • 11.15. South Korea

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2024
  • 12.2. FPNV Positioning Matrix, 2024
  • 12.3. Competitive Analysis
    • 12.3.1. Lonza Group Ltd
    • 12.3.2. Samsung Biologics Co., Ltd
    • 12.3.3. WuXi Biologics (Hong Kong) Co., Ltd
    • 12.3.4. Catalent, Inc.
    • 12.3.5. Boehringer Ingelheim International GmbH
    • 12.3.6. Fujifilm Diosynth Biotechnologies US, LLC
    • 12.3.7. Merck KGaA
    • 12.3.8. AGC Biologics Inc
    • 12.3.9. Thermo Fisher Scientific Inc.
    • 12.3.10. Rentschler Biopharma SE

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 5. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. NORTH AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 7. LATIN AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. EUROPE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. MIDDLE EAST ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. ASEAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. GCC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPEAN UNION ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. BRICS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. G7 ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. NATO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. ANTIBODIES CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 22. ANTIBODIES CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTIBODIES CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY HYDROPHOBIC INTERACTION CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY HYDROPHOBIC INTERACTION CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY HYDROPHOBIC INTERACTION CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY HYDROPHOBIC INTERACTION CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY HYDROPHOBIC INTERACTION CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY HYDROPHOBIC INTERACTION CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ION EXCHANGE CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY PROTEIN A CHROMATOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY PROTEIN A CHROMATOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY PROTEIN A CHROMATOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY PROTEIN A CHROMATOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY PROTEIN A CHROMATOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY PROTEIN A CHROMATOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY FILTRATION AND CENTRIFUGATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY FILTRATION AND CENTRIFUGATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY FILTRATION AND CENTRIFUGATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY FILTRATION AND CENTRIFUGATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY FILTRATION AND CENTRIFUGATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY FILTRATION AND CENTRIFUGATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ULTRAFILTRATION AND DIAFILTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ULTRAFILTRATION AND DIAFILTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ULTRAFILTRATION AND DIAFILTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ULTRAFILTRATION AND DIAFILTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ULTRAFILTRATION AND DIAFILTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY ULTRAFILTRATION AND DIAFILTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY BIOREACTOR OPERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY BIOREACTOR OPERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY BIOREACTOR OPERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY BIOREACTOR OPERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY BIOREACTOR OPERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY BIOREACTOR OPERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CELL LINE DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CELL LINE DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CELL LINE DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CELL LINE DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CELL LINE DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CELL LINE DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MEDIA AND FEED PREPARATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MEDIA AND FEED PREPARATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MEDIA AND FEED PREPARATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MEDIA AND FEED PREPARATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MEDIA AND FEED PREPARATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY MEDIA AND FEED PREPARATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 74. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 75. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 76. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 77. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 78. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 79. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 80. AMERICAS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. NORTH AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 84. NORTH AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 86. NORTH AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 88. NORTH AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. LATIN AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 92. LATIN AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 94. LATIN AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 96. LATIN AMERICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 105. EUROPE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. EUROPE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. EUROPE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 108. EUROPE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 109. EUROPE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 110. EUROPE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 111. EUROPE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 112. EUROPE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. MIDDLE EAST ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 116. MIDDLE EAST ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 118. MIDDLE EAST ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 120. MIDDLE EAST ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 121. AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 124. AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 125. AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 126. AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 127. AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 128. AFRICA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. ASEAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. ASEAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. ASEAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 142. ASEAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 143. ASEAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 144. ASEAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 145. ASEAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 146. ASEAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 147. GCC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GCC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GCC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 150. GCC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 151. GCC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 152. GCC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 153. GCC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 154. GCC ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. EUROPEAN UNION ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 158. EUROPEAN UNION ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 160. EUROPEAN UNION ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 162. EUROPEAN UNION ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 163. BRICS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. BRICS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. BRICS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 166. BRICS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 167. BRICS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 168. BRICS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 169. BRICS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 170. BRICS ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 171. G7 ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. G7 ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. G7 ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 174. G7 ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 175. G7 ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 176. G7 ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 177. G7 ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 178. G7 ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 179. NATO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. NATO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. NATO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 182. NATO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 183. NATO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 184. NATO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 185. NATO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 186. NATO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 190. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 191. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 192. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 193. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 194. UNITED STATES ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 195. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 196. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 197. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 198. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 199. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 200. CANADA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 201. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 202. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 203. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 204. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 205. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 206. MEXICO ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 207. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 208. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 209. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 210. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 211. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 212. BRAZIL ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 213. UNITED KINGDOM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 214. UNITED KINGDOM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 215. UNITED KINGDOM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 216. UNITED KINGDOM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 217. UNITED KINGDOM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 218. UNITED KINGDOM ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 219. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 220. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 221. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 222. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 223. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 224. GERMANY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 225. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 226. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 227. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 228. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 229. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 230. FRANCE ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 231. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 232. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 233. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 234. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 235. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 236. RUSSIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 237. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 238. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 239. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 240. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 241. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 242. ITALY ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 243. SPAIN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 244. SPAIN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 245. SPAIN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 246. SPAIN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 247. SPAIN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 248. SPAIN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 249. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 250. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 251. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 252. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 253. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 254. CHINA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 255. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 256. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 257. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 258. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 259. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 260. INDIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 261. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 262. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 263. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 264. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 265. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 266. JAPAN ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 267. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 268. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 269. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 270. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 271. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 272. AUSTRALIA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 273. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2018-2024 (USD MILLION)
  • TABLE 274. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY DOWNSTREAM, 2025-2032 (USD MILLION)
  • TABLE 275. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2018-2024 (USD MILLION)
  • TABLE 276. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY CHROMATOGRAPHY PURIFICATION, 2025-2032 (USD MILLION)
  • TABLE 277. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2018-2024 (USD MILLION)
  • TABLE 278. SOUTH KOREA ANTIBODIES CONTRACT MANUFACTURING MARKET SIZE, BY UPSTREAM, 2025-2032 (USD MILLION)
  • TABLE 279. ANTIBODIES CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 280. ANTIBODIES CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2024